TransCode Therapeutics Ownership | Who Owns TransCode Therapeutics?

TransCode Therapeutics Ownership Summary

TransCode Therapeutics is owned by 0.09% institutional investors, and 99.91% retail investors. Fidelity Extended Market Index is the top mutual fund, with 0.57% of its assets in TransCode Therapeutics shares.

RNAZ Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	TransCode Therapeutics	0.09%	-	99.91%
Sector	Healthcare Stocks	46.80%	8.14%	45.06%
Industry	Biotech Stocks	44.70%	7.99%	47.31%

Institutional Shareholders

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2023	11	-38.89%	262,198	-24.05%	-	633.44%	4	-73.33%	3	-
Dec 31, 2022	18	63.64%	345,210	-83.28%	-	18.95%	15	-	-	-100.00%
Sep 30, 2022	11	-8.33%	2,064,102	-0.99%	-	123.25%	-	-100.00%	3	50.00%
Jun 30, 2022	12	-	2,084,804	91.33%	-	455.76%	4	-	2	-50.00%
Mar 31, 2022	12	-14.29%	1,089,616	-53.71%	-	40.26%	4	-50.00%	4	300.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Extended Market Index	98.05K	0.57%	61.34K
Fidelity Series Total Market Index	22.62K	0.13%	22.62K
Fidelity Nasdaq Composite Index	1.09K	0.01%	-
State St US Extended Mkt Indx NL Cl C	26.00	0.00%	-
SSgA U.S. Extended Market Index Class I	1.03K	0.00%	-
SSgA U.S. Total Market Index Strategy	11.00	0.00%	3.00
NT Ext Equity Mkt Idx Fd - L	6.00	-	-
Spartan Extended Market Index Pool E	1.00	-	-
NT Ext Eq Mkt Indx Fd DC Lending Tier 5	2.00	-	1.00

Recent Insider Transactions

Date	Name	Role	Activity	Value
Sep 28, 2023	Fitzgerald Thomas A	Chief Financial Officer	Buy	$25.17K
Sep 28, 2023	Dudley Robert Michael	Chief Executive Officer	Buy	$49.98K
Jun 21, 2023	Dudley Robert Michael	Chief Executive Officer	Buy	$31.82K
Jun 20, 2023	Dudley Robert Michael	Chief Executive Officer	Buy	$16.85K
Jun 09, 2023	Dudley Robert Michael	Chief Executive Officer	Buy	$52.44K

Insider Transactions Trends

Date	Buy	Sell
2023 Q2	4	-
2022 Q4	-	-
2022 Q3	1	-
2022 Q2	2	-
2022 Q1	-	-

RNAZ Ownership FAQ

Who Owns TransCode Therapeutics?

TransCode Therapeutics shareholders are primarily institutional investors at 0.09%, followed by 0% insiders and 0% retail investors. The average institutional ownership in TransCode Therapeutics's industry, Biotech Stocks , is 44.70%, which TransCode Therapeutics falls below.

Does Blackrock own TransCode Therapeutics?

BlackRock is not among the top 10 institutional shareholders of TransCode Therapeutics.

Who is the top mutual fund holder of TransCode Therapeutics shares?

Fidelity Extended Market Index is the top mutual fund holder of TransCode Therapeutics shares, with 0.57% of its total shares outstanding invested in 98.05K TransCode Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools